Close menu

December 28th, 2023 | 07:05 CET

Liquidia, Cardiol Therapeutics, Bristol-Myers Squibb, Pfizer - Analysts comment on their favorites

  • Biotechnology
Photo credits:

The NASDAQ Biotechnology Index has been in the green since the beginning of the year with a mini gain of 1%, but the rebound since the lows at the end of October gives hope for a much more positive stock market year 2024 for the capital-intensive sector. In addition to the multiple interest rate hikes by the central banks, the biotech sector has been weighed down, in particular, by slower progress in research and development. With the expected start of a cycle of interest rate cuts, financing and capital costs are falling, which could lead to rising prices.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: LIQUIDIA TECH. DL-_001 | US53635D2027 , CARDIOL THERAPEUTICS | CA14161Y2006 , BRISTOL-MYERS SQUIBBDL-10 | US1101221083 , PFIZER INC. DL-_05 | US7170811035

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    Liquidia, Travere & Co. - These are Bank of America's biotech favorites

    The analysts at Bank of America identified four top picks from the second tier that could outperform the broad market in the coming year. Parameters such as a robust data situation, short-term catalysts, corresponding development phases and a positive regulatory outlook were taken into account. BridgeBio, Rocket, Liquidia and Travere are the companies that, according to experts, stand out, particularly in the final phase of approval and in the development of new products.

    Bank of America experts expect BridgeBio to receive approval soon for Acoramidis, which is considered an important advance in the treatment of a rare and deadly disease that can cause heart failure. At Liquidia, they see the imminent launch of Yutrepia as positive, although there is currently a legal dispute over approval. In the middle of the month, the Company lost an appeal for approval of Yutrepia, which means that approval could take a long time.

    Rocket Pharmaceuticals, on the other hand, is close to the first commercial approval of a gene therapy called RP-L201 for severe LAD-I, a rare genetic immune disorder that makes patients particularly susceptible to recurrent and fatal infections. The biotechnology company Travere, which specializes in CNS disorders, expects full approval of its drug Filspari, assuming the US Food and Drug Administration (FDA) grants approval.

    Cardiol Therapeutics - Experts see 600% opportunity

    If the analysts at Canaccord Genuity have their way, Cardiol Therapeutics shares should be among the stock market stars in the coming year. With a price target of USD 6.00, the Canadian analyst firm sees a price potential of well over 600% compared to the current share price, which is quoted at USD 0.85. One advantage that the experts emphasize compared to other biotech companies is the high cash position of over USD 30 million, which will enable the Company to press ahead with the development of the various studies until 2026 without further capital measures. In comparison, the stock market value is just USD 55.12 million.

    Speaking of studies and clinical programs, according to the management of the clinical-stage bioscience company, which is dedicated to the research and clinical development of anti-inflammatory and anti-fibrotic therapeutics for the treatment of heart disease, these are progressing faster than initially planned. In November, Cardiol Therapeutics announced the recruitment of more than 50% of the 25 patients required for the Phase II MAvERIC-Pilot study for the treatment of recurrent pericarditis. The study, which is expected to be completed in the first quarter of 2024, will be conducted by eight different research centres in the USA that specialize in the treatment of recurrent pericarditis.

    Also on board is the world-renowned Massachusetts General Hospital, Harvard Medical School's largest teaching hospital, which, according to Dr. Andrew Hamer, Chief Medical Officer and Head of Research and Development at Cardiol Therapeutics, also has the largest hospital-based research program in the country.

    In addition, the Company's drug candidate, CardiolRx™, is currently undergoing the Phase II ARCHER trial for acute myocarditis, which is testing not only safety and tolerability but also the impact on myocardial recovery. According to the experienced management team led by CEO David Elsley, this trial should be completed in the coming financial year.

    Given the high cash position and the advanced stages of the two programs, Cardiol Therapeutics' shares could be poised for a significant surge. Additionally, the Canadian company is likely becoming increasingly attractive for acquisition by a pharmaceutical giant.

    Bristol-Myers Squibb with billion-dollar deal

    Shortly before Christmas, the pharmaceutical giant from New York City put a present under the tree for itself and announced the acquisition of the biotech company Karuna for EUR 12.8 billion. With this move, the Group intends to strengthen its portfolio in the field of neuroscience. With an agreed purchase price of USD 330 per share, the offer is around 50% higher than the last closing price of Karuna shares.

    Karuna, a company in the biopharmaceutical sector, has a promising drug in development, KarXT, which is currently being reviewed by the US Food and Drug Administration (FDA) for possible approval for the treatment of schizophrenia. KarXT is also being researched for further applications in Alzheimer's disease and bipolar disorder.

    According to analysts, the drug, if approved, could generate annual sales of more than USD 6 billion in various therapeutic areas, as reported by the "Wall Street Journal". "We expect KarXT to drive our growth in the late 2020s and into the next decade," said Christopher Boerner", CEO of Bristol-Myers.

    In addition to falling interest rates, takeovers could boost the share prices of second-tier companies. The large pharmaceutical companies, for example, have over USD 100 billion in cash at their disposal. Biotech companies, on the other hand, are attractive takeover candidates due to the sometimes exaggerated correction of recent years. In particular, the oncology, weight loss and neurology sectors are likely to drive mergers and acquisitions in the coming year, said Jefferies analyst Michael Yee on CNBC's "Fast Money" program last Friday.

    The names he expects to be most involved in mergers and acquisitions in 2024 include Bristol-Myers, Pfizer, Merck and Gilead. Yee is convinced that the anti-inflation law will encourage pharmaceutical giants to "do more deals".

    The biotech sector could outperform in the coming year as interest rates are cut back. Bristol-Myers Squibb announced another billion-dollar acquisition shortly before Christmas. The wave of acquisitions is expected to gain momentum in 2024, with Cardiol Therapeutics being considered a promising candidate for a merger.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.


    Commented by André Will-Laudien on February 16th, 2024 | 07:00 CET

    MorphoSys and Cardiol Therapeutics in upward mode, while Bayer and Pfizer are in slow mode

    • Biotechnology
    • Pharma

    The biotech sector has made a very differentiated start to the new year. While the old favorites are barely moving, the second-line stocks MorphoSys and Cardiol Therapeutics are making a real splash. At Bayer, the bad news just won't go away, and despite a successful major takeover, Pfizer has not yet found its forward gear. After a rally of almost 15% in December, the Nasdaq Biotechnology Index (NBI) has taken a pause in the current year. Now, everyone is waiting for the first interest rate cut by central banks. Inflation is already falling, and the negative economic data for the Eurozone is increasing. The ECB would normally be in demand. What should investors urgently keep an eye on?


    Commented by Armin Schulz on February 12th, 2024 | 07:00 CET

    MorphoSys, Defence Therapeutics, Bayer - Biotech and Pharma suddenly back in focus

    • Biotechnology
    • Pharma

    Biotech ETFs have been on the rise since the end of October 2023. German biotech companies were able to raise more funds again last year. There are increasing signs that the tough times for investors in biotech and pharmaceutical companies are over. There is also growing activity on the takeover side. Most recently, the takeover bid from Novartis shifted the focus to companies in the healthcare sector. The Swiss pharmaceutical company wants to acquire MorphoSys for EUR 2.7 billion and thus fill up its oncology pipeline. We have selected three companies from the biotech and pharma sectors and examined their current situation.